Needham analyst Mike Matson upgraded Haemonetics (NYSE: HAE) from Hold to Buy with a price target of $112.00.The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE